Drug intelligence / Profile preview

Melaleuca tablet

Development stage: Unknown
Lead developer: Shanghai Public Health Clinical Center
Modality: Small Molecules
Administration: Oral

Overview

Melaleuca tablet is an investigational oral botanical drug candidate being developed by the Shanghai Public Health Clinical Center for the treatment of hepatocellular carcinoma (HCC). The drug is derived from extracts of the Melaleuca plant genus, which is known to contain various bioactive compounds, including triterpenoids such as melaleucic acid that have demonstrated preclinical anti-tumor activity through the induction of apoptosis and inhibition of tumor cell proliferation. As of 2021, Melaleuca tablet entered Phase I clinical development (ChiCTR2100051434) to evaluate its safety, tolerability, and pharmacokinetic profile in healthy adult volunteers, including assessments of the impact of food on its absorption and bioavailability.

Other names: Melaleuca

Beyond the preview

Go deeper on Melaleuca tablet.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Melaleuca tablet.

Explore the full profile